Biologically Intact Therapeutic Exosomes From Human Hepatic Progenitor Cells for Liver Diseases

Area of Science:

• Hepatology
• Cell Biology
• Biotechnology

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD) are increasing globally.
• Current treatments for MASLD and ALD are limited, and exosome-based therapies face challenges with biological integrity.

Purpose of the Study:

• To investigate the therapeutic potential of biologically intact exosomes for treating steatotic liver diseases.
• To assess the efficacy of exosomes in reducing lipid accumulation in MASLD and ALD models.

Main Methods:

• Biologically intact exosomes (30-200 nm) were isolated using the BEST technology, confirmed by CD63 and CD81 markers.
• Steatotic liver disease models were created in AML12 cells using oleic acid and ethanol, maintaining high cell viability.
• Exosomes containing hsa-miR-122-5p and hsa-miR-27a-3p were administered to disease models.

Main Results:

• Intact exosomes significantly reduced lipid accumulation in MASLD models by up to 92.7% and in ALD models by 93.2%.
• Treatment was effective at a dosage of 100 µg/mL of intact exosomes over 72 hours.
• The method maintained approximately 90% cell viability compared to normal hepatocytes.

Conclusions:

• Biologically intact exosomes demonstrate significant therapeutic effects in reducing liver steatosis.
• Exosome-based cell-free therapy holds potential for reversing MASLD and ALD.
• This approach offers a promising strategy for treating prevalent liver diseases.